VPA does not enhance platinum binding to DNA in
cisplatin-resistant neuroblastoma cancer cells

J 2017

VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells

RAUDENSKÁ, Martina, Ludmila KREJCOVA, Lukas RICHTERA, Zbynek HEGER, Jan HRABETA et. al.

Základní údaje

Originální název

VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells

Autoři

RAUDENSKÁ, Martina (203 Česká republika, domácí), Ludmila KREJCOVA (203 Česká republika), Lukas RICHTERA (203 Česká republika), Zbynek HEGER (203 Česká republika), Jan HRABETA (203 Česká republika), Tomas ECKSCHLAGER (203 Česká republika), Marie STIBOROVA (203 Česká republika), Vojtech ADAM (203 Česká republika), Monika KRATOCHVÍLOVÁ (203 Česká republika, domácí), Michal MASAŘÍK (203 Česká republika, domácí) a Jaromír GUMULEC (203 Česká republika, garant, domácí)

Vydání

Tumor Biology, London, Sage Publications INC, 2017, 1010-4283

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30105 Physiology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.650 v roce 2016

Kód RIV

RIV/00216224:14110/17:00097820

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1177/1010428317711656

Klíčová slova anglicky

Neuroblastoma; cisplatin; resistance; valproate; hypoxia; oxidative stress

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 3. 2018 11:39, Soňa Böhmová

Anotace

V originále

Neuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valproate on neuroblastoma cells. Nevertheless, these studies omitted effects of hypoxia, despite its undeniable tumorigenic role. In this study, we addressed the question whether valproate promotes binding of platinum-based anti-cancer drugs (cisplatin, carboplatin and oxaliplatin) to DNA and role of hypoxia, cellular antioxidant capacity and cisplatin resistance in this process. Following parameters differed significantly when cells were exposed to treatment with platinum-based drugs: elevation of platinum content bound to DNA, elevation of total thiol content, GSH/GSSG ratio, glutathione reductase and peroxidase, superoxide dismutase and elevation of antioxidant capacity. Hypoxia caused a decrease in cytosine/adenine peak, and no changes in platinum-DNA binding properties were observed. After valproate co-treatment, oxidative stress-related parameters and cytosine/adenine peak were only elevated. The amount of platinum bound to DNA was not changed significantly. Valproate is not able to enhance platinum binding to DNA in neuroblastoma cells, neither in case of intrinsic resistance (UKF-NB-4) nor in case of acquired resistance (UKF-NB-4CDDf'). Therefore, another mechanism different from increase in platinum binding to DNA should be considered as a synergistic effect of valproate by cisplatin treatment.

Citovat

RAUDENSKÁ, Martina, Ludmila KREJCOVA, Lukas RICHTERA, Zbynek HEGER, Jan HRABETA, Tomas ECKSCHLAGER, Marie STIBOROVA, Vojtech ADAM, Monika KRATOCHVÍLOVÁ, Michal MASAŘÍK a Jaromír GUMULEC. VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells. Tumor Biology. London: Sage Publications INC, 2017, roč. 39, č. 9, s. 1-8. ISSN 1010-4283. Dostupné z: https://dx.doi.org/10.1177/1010428317711656.

@article{1391657,
   author = {Raudenská, Martina and Krejcova, Ludmila and Richtera, Lukas and Heger, Zbynek and Hrabeta, Jan and Eckschlager, Tomas and Stiborova, Marie and Adam, Vojtech and Kratochvílová, Monika and Masařík, Michal and Gumulec, Jaromír},
   article_location = {London},
   article_number = {9},
   doi = {http://dx.doi.org/10.1177/1010428317711656},
   keywords = {Neuroblastoma; cisplatin; resistance; valproate; hypoxia; oxidative stress},
   language = {eng},
   issn = {1010-4283},
   journal = {Tumor Biology},
   title = {VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells},
   volume = {39},
   year = {2017}
}

TY  - JOUR
ID  - 1391657
AU  - Raudenská, Martina - Krejcova, Ludmila - Richtera, Lukas - Heger, Zbynek - Hrabeta, Jan - Eckschlager, Tomas - Stiborova, Marie - Adam, Vojtech - Kratochvílová, Monika - Masařík, Michal - Gumulec, Jaromír
PY  - 2017
TI  - VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
JF  - Tumor Biology
VL  - 39
IS  - 9
SP  - 1-8
EP  - 1-8
PB  - Sage Publications INC
SN  - 10104283
KW  - Neuroblastoma
KW  - cisplatin
KW  - resistance
KW  - valproate
KW  - hypoxia
KW  - oxidative stress
N2  - Neuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valproate on neuroblastoma cells. Nevertheless, these studies omitted effects of hypoxia, despite its undeniable tumorigenic role. In this study, we addressed the question whether valproate promotes binding of platinum-based anti-cancer drugs (cisplatin, carboplatin and oxaliplatin) to DNA and role of hypoxia, cellular antioxidant capacity and cisplatin resistance in this process. Following parameters differed significantly when cells were exposed to treatment with platinum-based drugs: elevation of platinum content bound to DNA, elevation of total thiol content, GSH/GSSG ratio, glutathione reductase and peroxidase, superoxide dismutase and elevation of antioxidant capacity. Hypoxia caused a decrease in cytosine/adenine peak, and no changes in platinum-DNA binding properties were observed. After valproate co-treatment, oxidative stress-related parameters and cytosine/adenine peak were only elevated. The amount of platinum bound to DNA was not changed significantly. Valproate is not able to enhance platinum binding to DNA in neuroblastoma cells, neither in case of intrinsic resistance (UKF-NB-4) nor in case of acquired resistance (UKF-NB-4CDDf'). Therefore, another mechanism different from increase in platinum binding to DNA should be considered as a synergistic effect of valproate by cisplatin treatment.
ER  -

RAUDENSKÁ, Martina, Ludmila KREJCOVA, Lukas RICHTERA, Zbynek HEGER, Jan HRABETA, Tomas ECKSCHLAGER, Marie STIBOROVA, Vojtech ADAM, Monika KRATOCHVÍLOVÁ, Michal MASAŘÍK a Jaromír GUMULEC. VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells. \textit{Tumor Biology}. London: Sage Publications INC, 2017, roč.~39, č.~9, s.~1-8. ISSN~1010-4283. Dostupné z: https://dx.doi.org/10.1177/1010428317711656.

Podrobný výpis o publikaci